Release of Negotiated Prices Under Inflation Reduction Act Reveals that BRENZAVVY® (bexagliflozin) Remains the Lowest Priced SGLT2 Inhibitor

MARLBOROUGH, Mass.–(BUSINESS WIRE)–TheracosBio today announced that, in the wake of the federal government release of negotiated prices under the Medicare Drug Price Negotiation Program, BRENZAVVY® (bexagliflozin) remains the lowest priced sodium-glucose cotransporter 2 (SGLT2) as compared to the Negotiated Monthly List Price, also referred to as the Maximum Fair Price, for other drugs in the SGLT2 class. “While we salute the work that the federal government is doing to reduce the cost of pha